Table 5 Most important treatment goals
Symptom Quartile | Prognostic Risk | ||||
|---|---|---|---|---|---|
Treatment Goal,a n (%) | All Respondents | Q4 | Q1 | High | Low |
MF | n = 207 | n = 73 | n = 43 | n = 63 | n = 9 |
Slow/delay progression of condition | 86 (42) | 27 (37) | 18 (42) | 28 (44) | 6 (67) |
Better QoL | 43 (21) | 26 (36) | 2 (5) | 16 (25) | 0 |
Healthy blood counts | 23 (11) | 6 (8) | 10 (23) | 5 (8) | 1 (11) |
Symptom improvement | 14 (7) | 5 (7) | 1 (2) | 1 (2) | 1 (11) |
Reduction in spleen size | 13 (6) | 2 (3) | 5 (12) | 3 (5) | 0 |
Reduce blood transfusions | 12 (6) | 4 (6) | 2 (5) | 6 (10) | 0 |
PV | n = 380 | n = 98 | n = 88 | n = 101 | n = 26 |
Slow/delay progression of condition | 96 (25) | 23 (24) | 21 (24) | 20 (20) | 7 (27) |
Prevention of vascular/thrombotic events | 92 (24) | 17 (17) | 16 (18) | 25 (25) | 5 (19) |
Healthy blood counts | 68 (18) | 10 (10) | 27 (31) | 22 (22) | 3 (12) |
Better QoL | 45 (12) | 19 (19) | 5 (6) | 11 (11) | 4 (15) |
Symptom improvement | 33 (9) | 21 (21) | 1 (1) | 6 (6) | 2 (8) |
Hematocrit levels <45 % | 22 (6) | 4 (4) | 9 (10) | 9 (9) | 1 (4) |
ET | n = 226 | n = 42 | n = 71 | n = 35 | n = 46 |
Prevention of vascular/thrombotic events | 78 (35) | 9 (21) | 28 (39) | 12 (34) | 15 (33) |
Slow/delay progression of condition | 48 (21) | 8 (19) | 16 (23) | 5 (14) | 14 (30) |
Healthy blood counts | 39 (17) | 5 (12) | 18 (25) | 5 (14) | 4 (9) |
Better QoL | 31 (14) | 14 (33) | 2 (3) | 3 (9) | 9 (20) |
Symptom improvement | 21 (9) | 3 (7) | 3 (4) | 6 (17) | 2 (4) |